SEC Form 4 · accession 0001104659-17-022530
Cardiff Oncology, Inc. · CRDF
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William J Welch
Officer — CEO · Director
Period of report
Apr 7, 2017
Accepted (ET)
Apr 10, 2017 · 4:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001213037
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Apr 7, 2017 | A | 130,000 | A | — | — | Common Stock | 130,000 | 330,000 | D |
Explanation of responses
- F1Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock.
- F2The RSUs shall vest on January 30, 2018 provided that the reporting person provides continuous service to Trovagene, Inc.